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Abstract 
Objectives 
We investigated whether baseline laboratory findings change provider prescribing behavior for 
HIV post-exposure prophylaxis.  
Methods 
A retrospective review of occupational health records from a large, tertiary care academic 
medical center was conducted. Subjects were healthcare providers (HCP) with clinical or 
research exposure to HIV who completed a 28-day course of once daily tenofovir 
disoproxil/emtricitabine (245/200 mg) plus twice daily raltegravir (400 mg). Basic demographic 
information, exposure information and laboratory values were obtained from the medical record.  
Results 
Between January 1, 2012, and May 12, 2016, 64 HCP completed a 28-day course of post-
exposure prophylaxis (PEP). Two HCP presented with laboratory abnormalities at baseline 
{renal (1), hepatic (1)} and three HCP had abnormal changes at two weeks compared to baseline 
{renal (2), hematologic (1)}; however, none of the abnormalities led to modification or 
discontinuation of PEP. There were no HIV seroconversions throughout the study period.  
Conclusion 
Our five-year experience of prescribing PEP at a large academic medical center suggests that 
baseline assessment of renal, hematologic and hepatic function is unnecessary when starting the 
HIV post-exposure prophylaxis regimen of tenofovir disoproxil/emtricitabine/raltegravir. Given 
that HCP are generally a healthy population, that hepatic or renal dose adjustments are not 
required for this PEP regimen and that this course of PEP is well-tolerated it appears that 
baseline laboratory testing is unnecessary. Elimination of routine renal, hematologic and hepatic 
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function studies in occupational HIV exposures should be considered as a way to improve the 
timeliness of starting PEP after exposure as well as eliminate the barrier of seeking immediate 
care after exposure beyond obtaining PEP medications.   
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Introduction 
 The prevention of occupationally acquired human immunodeficiency virus (HIV) 
infection in the US is by all accounts a public and occupational health success story. From 1985 
to 2013, there were 58 confirmed cases of occupationally acquired HIV infections in healthcare 
providers (HCP), with an additional 150 possible cases (CDC Division of HIV/AIDS 
Prevention). However, with more effective post-exposure prophylaxis (PEP) regimens and 
improved compliance as therapies have become more tolerable, there has only been one 
confirmed occupationally acquired HIV infection in a health care worker since 1999 (CDC 
Division of HIV/AIDS Prevention). 
 The success in prevention of occupationally acquired HIV infections does not mean that 
continued efforts are not needed. Approximately 385,000 sharps-related injuries occur each year 
to hospital-based HCP (CDC, 2011). While sharps-related injuries in nonsurgical hospital 
settings decreased by 31.6% in the first five years after the Needlestick and Safety Prevention 
Act of 2000, sharps-related injuries in surgical hospital settings increased by 6.5% over the same 
time frame (CDC, 2011). The prevalence of HIV is another factor to consider. By the end of 
2012, an estimated 1.2 million people aged 13 and older were living with HIV in the United 
States, including 156,300 (12.8%) people who had yet to be diagnosed (CDC, 2015). This 
number has been stable from 2010 to 2014, so incidental occupational transmission is still a 
problem.  
HIV continues to be a disease with substantial morbidity and thus it is important to 
prevent transmission of HIV whenever possible. To this end, HIV PEP has been used since the 
late 1980s as a way to reduce the chances of HIV seroconversion in exposed individuals. Formal 
support for HIV PEP medications first appeared in 1996 in the US Public Health Service (PHS) 
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guidelines (CDC, 1996). Because the HIV medications used in 1996, namely zidovudine (ZDV), 
lamuvidine (3TC), and indinavir (IDV) exhibited significant toxicity (Lee & Henderson, 2001), 
early guidelines recommended monitoring of laboratory values for complete blood count, renal, 
and hepatic function tests at baseline, and at 2 weeks (CDC, 1996).  To this day, the New York 
State Department of Health AIDS Institute, recommends laboratory monitoring at baseline, 2 
weeks, and 4 weeks (New York State Department of Health AIDS Institute, 2016).  
The medications of the past were not well tolerated due to both high pill burden and 
toxicity, and this adversely affected adherence (Parkin, et al., 2000). Research has led to many 
advancements in HIV medications since the support of the initial PEP regimen in 1996. The 
current standard of care for HIV PEP is a 3-drug regimen of once daily tenofovir 
disoproxil/emtricitabine (245/200 mg) plus twice daily raltegravir (400 mg) and is neither renally 
nor hepatically dosed (Kuhar, et al., 2013). This 3-drug regimen is also the preferred 
combination for antiretroviral-naïve HIV infected pregnant women (Panel on Treatment of HIV-
Infected Pregnant Women and Prevention of Perinatal Transmission, 2016) and is recommended 
for non-occupational post-exposure prophylaxis (nPEP) (McAllister, et al., 2013). While the US 
Public Health Service guidelines for PEP have been updated 3 times since 1996, the provision 
for the drug toxicity monitoring has remained unchanged since 1996, despite the greatly 
improved side effect profile of the current 3-medication PEP regimen (Kuhar, et al., 2013). 
The drug toxicity monitoring itself costs money. Given these costs, and the fact that the 
drug toxicity monitoring provision has not been updated despite the PEP medication 
advancements, we were interested in exploring whether baseline laboratory findings influenced 
the course of care for HIV PEP. 
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Systematic Review of Previous Literature 
Introduction 
 The intent of this systematic review was to identify existing studies that examined 
baseline laboratory tests (hepatic, renal, and hematologic) in the setting of HIV PEP, and to see 
how these test results were related to adherence and toxicity. A brief background on the 
medications that comprise the PEP regimen will be presented followed by the systematic review. 
 Emtricitabine-tenofovir (FTC-TDF) is a co-formulation that is produced by Gilead 
Sciences. Emtricitabine is a nucleoside reverse transcriptase inhibitor. Tenofovir is a nucleotide 
reverse transcriptase inhibitor. Reverse transcriptase is a key viral enzyme made by retroviruses 
such as HIV and hepatitis B used to convert its RNA into DNA that can then be inserted into the 
host’s DNA.  
 The combination of emtricitabine-tenofovir gained its first FDA approval in 2004 
(FDA.gov, 2016). It is often paired with either a protease inhibitor such as lopinavir (combined 
with ritonavir), or with an integrase strand inhibitor such as raltegravir. It is FDA approved as a 
component of HIV therapy. It is also FDA approved for pre-exposure prophylaxis (PrEP) for 
prevention of HIV infection. Its off-label uses include: hepatitis B treatment in patients with 
antiviral-resistant HBV or coinfection with HIV, PrEP for prevention of HIV infection in 
injecting drug users (IDU) who are at risk for parenteral acquisition of HIV but not at risk for 
sexual acquisition of HIV, and occupational PEP. 
 Raltegravir (RAL) is a drug in the integrase inhibitor class, and is produced by Merck. It 
operates by inhibiting virus’ integrase enzyme. The enzyme functions to incorporate viral DNA 
into the genome of the host cell. Raltegravir thus works by inhibiting the integration of viral 
DNA into the host’s DNA. It has a theoretical advantage over protease inhibitors because it halts 
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the HIV infection process before HIV integrates into the host’s DNA, as opposed to protease 
inhibitors which intervene after the DNA already has been integrated into the host DNA. 
Raltegravir was the first approved integrase inhibitor for clinical use in both treatment-naïve and 
treatment-experienced patients. It gained FDA approval in October 2007 (FDA.gov, 2016). It is 
FDA approved for treatment of HIV-1 infection in combination with other antiretroviral agents. 
Off-label usage includes PEP for occupational (and non-occupational) exposure to HIV. 
 The combination 3 drug regimen of emtricitabine-tenofovir plus raltegravir was first 
supported in the US Public Health Service Guidelines for PEP in 2013 (Kuhar, et al., 2013). It is 
now the preferred regimen. 
Methods 
Search Strategy: PubMED and SCOPUS were searched on June 18, 2016 to identify possible 
studies. As each database is indexed differently and has a different set of studies,  slightly 
different searches were conducted in each of the databases.  
PubMED was searched using the term “raltegravir tenofovir emtricitabine”. This produced 138 
results. SCOPUS was searched using the term “raltegravir tenofovir emtricitabine (adverse 
effects OR tolerability OR side effects)”. This produced 117 results.  
Selection Criteria: Articles chosen for review met the following criteria: involved the HIV 
raltegravir-tenofovir-emtricitabine regimen, involved human subjects, had been conducted in the 
last 5 years, be written in English, and contained metrics (either qualitative or quantitative) 
regarding adherence or tolerability.  The full article had to be available via PubMED or 
SCOPUS. Only data that had been published or presented in a peer-reviewed setting were 
considered. No case studies or pilot studies were reviewed. 
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Data Abstraction: Once an article was selected for full review, relevant data points were 
abstracted by a single author (Chima Ohadugha) from the publication and arranged in a table. 
These qualifications of the evidence presented are based on the type of study and by limitations 
to: study quality, consistency, certainty about directness, precision, bias, effect magnitude, 
statistical significance, and the potential for confounding.   
Results 
 The PubMED search produced 138 results. SCOPUS produced 117 results. These results 
were placed in RefWorks, and the duplicate studies were removed, as there was some overlap in 
the studies that were retrieved from the search of the 2 databases. After removing the duplicates, 
212 unique references remained. The abstracts of these articles were analyzed to determine the 
suitability of each article. The references of the articles were examined for relevant articles as 
well. Most articles were dealt with the incorrect PEP regimen, or did not address issues of 
adherence or side effects. Three relevant articles remained whose details are provided in Table 1.  
Analysis  
 The first article, the STARTMRK trial, was a randomized, blinded, double-dummy phase 
III trial (Rockstroh, et al., 2013). It compared raltegravir plus tenofovir/emtricitabine with 
efavirenz plus tenofovir/emtricitabine over the span of 5 years. The primary outcome was the 
percentage of subjects with viral RNA levels less than 50 copies/mL. Adherence and side effects 
were also measured via patient diaries, clinician pill counts, and clinical evaluations. In the 
study, 281 people were randomized to the raltegravir group. Patients were 81% male, 41% white, 
with a median age of 37.6 years. The majority of subjects were from the Latin American site 
(35.2%), with the remaining from Southeast Asia (12.1%), North America (29.2%), and Europe 
(23.5%).  
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Drug-related clinical adverse events were reported in 146 raltegravir recipients (52.0%). 
Laboratory adverse events were reported in 56 patients (19.9%). Zero patients discontinued due 
to laboratory abnormalities. 
 A main strength of the study was its design (randomized, blinded). Another strength was 
that the study reported the number of people who discontinued the treatment due to laboratory 
abnormalities. A weakness of the study stemmed from the fact that pill counting was used to 
monitor adherence, as the patients may have done pill-dumping in order to appease the clinician. 
A potential limitation was that many investigators (Rockstroh, Dejesus, etc.) were paid 
consultants at various pharmaceutical companies, including Merck and Gilead.  
 The second article described the QDMRK trial was a randomized, double-blind, phase 3 
non-inferiority study (Eron, et al., 2011). Patients were randomly assigned to receive tenofovir-
emtricitabine plus either 400mg BID raltegravir or once daily 800mg raltegravir. The primary 
outcome was virological response at 48 weeks in patients who received at least 1 dose of study 
drug. Adherence and drug side effects was also monitored.  
 The patients were from 83 centers on six contents. Most (72%) were white. Eighty-two 
percent were male. The median age was 38. There were 775 enrolled patients, with 388 
randomly allocated to receive raltegravir BID, with the remainder receiving raltegravir once 
daily. Median time spent in study for the participants was 68 weeks.  
 Of the BID raltegravir group, 11% had abnormal laboratory values, and 2.3% had drug-
related laboratory adverse events. In the trial, there were 0 reports of serious drug related adverse 
effects, and discontinuations due to adverse effects. The most common grade 3 or 4 laboratory 
abnormalities were increased creatine kinase (5% of participants) without any reported 
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rhabdomyolysis. Alanine aminotransferase levels were >5 times ULN in 13/386 (3.4%) of 
participants. Absolute neutrophil count was <750/µL in 5/386 (1.3%) of cases. 
 A main strength of the study was the study design. Another strength was that the study 
was designed to report adverse events and laboratory abnormalities explicitly (using MedDRA 
version 11.0). Potential limitations include the fact that many of the investigators have been paid 
pharmaceutical consultants. Also Merck has sponsored the study. This may play a role because 
the investigators were the people who decided whether an adverse effect was drug-related. 
 The third study, by McAllister et al, dealt with HIV-uninfected men evaluated in 
Australia for non-occupational PEP (McAllister, et al., 2013). 86 were prescribed the tenofovir-
emtricitabine-raltegravir regimen, and 34 were prescribed tenofovir-emtricitabine.  Adherence 
(measured by pill count) and adverse events were assessed at weeks 1, 2 and 4. The study 
participants received extended education about the importance of adherence. There were non-
study controls who chose not to enter the study, who did not receive the extra counselling. The 
study was a non-randomized, controlled, prospective study.  
 Adherence rate was 92%. The 91 RAL-FTC-TDF recipients reported 260 adverse events 
(mean 2.9/person). All subjective adverse events were either grade 1 or 2, and 82% were 
possibly, probably or definitely related to study drug. Nine percent developed mild myalgias, 
with 4 developing transient grade 4 elevations in creatine kinase, which spontaneously resolved 
by week 4. Grade 1−2 elevations in alanine and aspartate aminotransferases occurred in 28 
(22%) study participants but grade 3 or 4 was uncommon (2%). 
 A strength of the study, with regards to our question, is that it examined the HIV 
medications specifically in the context of PEP. The other 2 studies, in contrast, examined the 
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HIV medications in the context of persons diagnosed with HIV requiring a lifelong treatment 
course . A limitation of the study was that the participants received more education about 
adherence, and text message reminders than perhaps the general population would. Like the 
other studies, pill count was used for adherence, which is a potential limitation.  
Implications of Findings: This review, which includes 755 patients, suggests that the 3-drug 
regimen is well-tolerated, and that adherence is high. As such, it also suggests that routine 
laboratory studies for medication-related abnormalities may be unnecessary for short-term PEP.  
The paucity of studies specifically examining occupational PEP regimens suggests that more 
attention could be directed towards occupational PEP.  
Methods 
Data Abstraction 
A retrospective chart review of University and Hospital HCP of the University of North 
Carolina at Chapel Hill evaluated for PEP, between January 1, 2012, and May 12, 2016, was 
conducted. The University HCP (researchers, students, and anyone with a University faculty 
appointment) were evaluated at the University Employee Occupational Health Clinic and the 
Hospital HCP were evaluated at the UNC Hospitals Occupational Health Services. Of note, 
attendings with faculty appointments are regarded as University HCP. While both occupational 
health clinics use the same HIV PEP protocol, each clinical site operates independently. Since 
the data were recorded and organized differently between the two sites, the process of the data 
abstraction differed, and thus will be discussed for each site individually. 
For the University Employee Occupational Health Clinic (Medical Drive) location, a list 
of HCP who received HIV PEP was not readily available. A list of these HCP was derived as 
follows. First, a list of HCP who had a filed a workman’s compensation report during the years 
14 
 
of interested was gathered. Within this group, HCP who had undergone laboratory tests for 
blood-borne pathogen exposures (BBPE) were then identified.  Of note, this group included HCP 
who had exposures to a wide array of sources, including unknown sources, known HIV positive 
sources, known HIV negative sources, and known hepatitis B sources. 
All of the medical records of the HCP with BBPE laboratory tests were examined. Most 
of these were  medical charts located within the building (organized in alphabetical order), and 
some were archived in PDF format on the secured computers within the building. UNC’s 
Personal Identification Number (PID) and name were used to identify each patient. If the chart 
contained a PEP prescription, then the chart was abstracted and the data was placed in a secured 
cabinet for subsequent analysis.  
For the UNC Hospitals Occupational Health Services (Manning Drive) location, the 
information for Hospital HCP who were prescribed HIV PEP was stored differently. The HCP 
medical records (in the form of physical charts or archived compact discs) were located onsite. 
The charts were all organized by medical record number (MRN).  
A list of HCP who received PEP is kept onsite in a set of booklets, separate from the 
medical records. The booklet contains the employee name, and either the MRN or an internal 
number called the “Z number”. Since the booklets did not always contain the HCP MRNs, we 
used a separate list called the “Z-list”, to map the HCP names to their respective MRNs. The 
MRN number was then used to locate the charts. If the  charts were not found, they were marked 
to be located in the archives. The archives consisted of a set of compact discs which contained 
scanned copies of the medical records.  
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Inclusion Criteria 
Subjects had to be Hospital or University HCP of UNC Chapel Hill who were prescribed 
HIV PEP for an occupational pathogen exposure from January 1, 2012 to May 12, 2016. This 
includes physicians, nurses, other healthcare personnel, and research staff. Potential HIV sources 
could be either known HIV positive, or of unknown HIV status. If there was any documentation 
of the source being found negative, then the employee was excluded from the data set. 
Employees were only included if they were prescribed the newer 3-drug regimen of raltegravir-
emtricitabine-tenofovir. HCP given the older 4-drug regimen emtricitabine-tenofovir plus 
lopinavir-ritonavir were excluded from the analysis. Baseline demographics are provided in 
Table 2.  
Exclusion of HCP taking the 4-drug regimen 
 Four HCP were not included in the analysis because they had received a 4-drug regimen 
(emtricitabine-tenofovir plus lopinavir-ritonavir) instead of the 3-drug regimen tenofovir-
emtricitabine plus raltegravir.   
Lab Values Collected 
     For each subject that passed the selection criteria, basic demographic information, 
pathogen exposure information (source HIV status and route of exposure), and laboratory values 
were obtained. The labs include white blood cell count (10^9/L), hemoglobin (g/dL), hematocrit 
(%), platelets (10^9/L), absolute neutrophil count (10^9/L), serum creatinine (mg/dL), total 
bilirubin (mg/dL), aspartate aminotransferase (U/L), alanine aminotransferase (U/L), and 
pregnancy test (either qualitative urine pregnancy or bHCG). These labs were recorded at 
baseline, 2 weeks, and 4 weeks, when available. Using Microsoft Excel 2013 (15.0.4823.1000) 
32-bit, data was arranged, and descriptive statistics and calculations were carried out.  
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Definitions of Hematologic, Renal, and Hepatic Dysfunction 
 Definitions for hematologic, renal, and hepatic dysfunction were established based on the 
Common Terminology Criteria for Adverse Events (National Cancer Institute, 2010). The 
definitions are outlined in the following. For additional information, see the Appendix. 
Definition of Hematologic Dysfunction 
 The hematologic dysfunction was defined by the presence of abnormalities in either 
hemoglobin or absolute neutrophil count. For our study, hematologic dysfunction was defined as 
any case where either hemoglobin <10.0 g/dL or ANC < 1.5x10^9/L. 
Definition of Renal Dysfunction  
 Renal function was calculated by the glomerular filtration rate (GFR). Renal dysfunction 
is defined by a GFR less than 60 mL/min per 1.73 m2. The GFR was estimated using the 4-
variable Modification of Diet in Renal Disease (MDRD) Study equation, which is nearly as 
accurate as the 6-variable MDRD equation (Levey, et al., 2006). At McLendon Labs, the 
calibration of serum creatinine results had been set to enable traceability to the internationally 
accepted isotope dilution mass spectrometry. As such, for the calculation of the GFR, the 
constant 175 was used, as outlined by the equation: 
GFR, in mL/min per 1.73 m2 = 175 * Serumcreatinine-1.154 * Age-0.203 * (0.742 if female) * (1.21 
if black) 
Definition of Hepatic Dysfunction  
 Hepatic dysfunction is defined as the presence of any of three conditions noted below. Of 
note, the upper limit of normal (ULN) at McLendon Labs for AST is 55 U/L, for ALT is 72 U/L, 
and for total bilirubin is 1.8 mg/dL. 
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 Condition 1: AST is greater than 3 times the upper limit of normal (ULN), that is, AST > 165 
U/L 
 Condition 2: ALT is greater than 3 times the upper limit of normal (ULN), that is, ALT >  216 
U/L 
 Condition 3: Total bilirubin is greater than 1.5 times the ULN, that is: total bilirubin > 1.8 mg/dL 
Ethics Statement 
 This medical records review was performed after completing an IRB and receiving 
approval by expedited review from the Institutional Review Board at the University of North 
Carolina at Chapel Hill. The data was stored and secured onsite. All patient records were de-
identified prior to analysis. 
Results 
Between January 1, 2012, and May 12, 2016, there were 78 HCP who were initially 
prescribed HIV PEP for an occupational exposure. Of those, 8 discontinued the PEP because the 
source patient was later confirmed to be HIV negative. Four HCP were prescribed the older 
regimen of emtricitabine-tenofovir plus lopinavir-ritonavir, and were also excluded from the 
original analysis. Two HCP had missing laboratory data, resulting in 64 HCP available for the 
final analysis. 
 The average age in the sample was 35 years (Table 1) with 57.9% female.  The most 
frequently reported exposure was needlestick injury (61.3%). The vast majority of the exposures 
(93.5%) occurred in the clinical setting, as opposed to a research setting. The HIV status of the 
source was known 83.3% of the time. The majority of HCP starting PEP were hospital-based 
HCP (82.8%). 
 All HCP were HIV negative at baseline. There were no HIV seroconversions throughout 
the study. During the study period, no employee was prescribed a PEP regimen for more than 
one occasion. Two HCP presented with laboratory abnormalities at baseline based on the values 
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from the Common Terminology Criteria for Adverse Events (National Cancer Institute, 2010). 
Three HCP had abnormal changes at two weeks compared to baseline {renal (2), hematologic 
(1)}. As shown in Table 3, the number of hematologic, renal, and hepatic lab abnormalities was 
modest.  
Hematologic Dysfunction 
 The lowest hemoglobin value in the data set was 10.8 g/dL. Thus, based on the 
hemoglobin values, there was no hematologic dysfunction. There was exactly one absolute 
neutrophil count (ANC)  value below the threshold of 1.5 * 109/L in the data sample. The patient 
had baseline ANC of 3.4 * 109/L , and a 2-week value of 1.4 * 109/L. There was no 4-week ANC 
recorded. The ANC of 1.4 * 109/L falls into the Grade 2 category of ANC between 1.0 * 109/L 
and 1.5 * 109/L. The Grade 2 designation signifies a moderate adverse effect, or that minimal, 
local, or noninvasive intervention may be indicated. 
Renal Dysfunction 
 On four occasions, the glomerular filtration rate (GFR)  was below the 60 
mL/min/1.73m2 threshold (with one subject having 2 of these sub-threshold GFRs). One of the 
subjects had a GFR of 51.8 mL/min/1.73m2 at baseline, and a GFR of 52.9 mL/min/1.73m2 at 
week 2 (there was no week 4 serum creatinine measure taken). Another subject had baseline, 2-
week, and 4-week GFRs of 73.3 mL/min/1.73m2, 58.5 mL/min/1.73m2, and 68.3 mL/min/1.73m2 
respectively. The third subject had baseline, 2-week, and 4-week GFRs of 69.5 mL/min/1.73m2, 
58.5 mL/min/1.73m2, and 67.9 mL/min/1.73m2 respectively. In both of the last 2 cases, the 
abnormal GFR occurred at week 2 and fully resolved by week 4 without intervention. Based on 
the Common Terminology Criteria for Adverse Events, all of the abnormal GFRs 51.8 
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mL/min/1.73m2, 52.9 mL/min/1.73m2, 58.5 mL/min/1.73m2, and 58.5 mL/min/1.73m2 fall into 
the Grade 2 category (GFR in the range of 30-59 mL/min/1.73m2). 
Hepatic Dysfunction 
 The highest aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the 
sample were 113 U/L and 183 U/L, respectively. As such, none of the AST or ALT values 
satisfied the criteria for hepatic dysfunction. One subject had a total bilirubin > 1.8 mg/dL on two 
separate occasions: on baseline (2.5 mg/dL) and at 4 weeks (1.9 mg/dL). The 2-week value was 
not recorded. 
Four-Drug Regimen 
 Four subjects were excluded from the initial analysis because they were given the 4-drug 
regimen instead of the 3-drug regimen. The 4 subjects did not meet the criteria for hematologic 
(lowest hemoglobin: 10.8 g/dL, lowest ANC: 2.3 * 109/L), renal dysfunction (lowest GFR: 70.4 
mL/min/1.73m2), or hepatic dysfunction (highest AST: 81 U/L, highest ALT: 207 U/L, highest 
total bilirubin: 1.1 mg/dL). 
Discussion 
This study examined the HIV PEP protocol with a specific focus on the routine 
obtainment of laboratory values other than baseline HIV testing. For the 64 subjects in the time 
period, a total of 782 laboratory tests were drawn for hemoglobin, ANC, GFR, AST, ALT, and 
total bilirubin. Five laboratory abnormalities were identified in five different HCP:  three were 
mild renal abnormalities, one was a mild hematologic abnormality, and one was a mild hepatic 
abnormality. In other words, 5/64 (8%) HCP exhibited laboratory abnormalities, and 5/782 
(0.6%) laboratory tests were abnormal. None of the abnormalities necessitated PEP modification 
or discontinuation.   It is important to note that the normal ranges for laboratory tests are 
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typically based on 95% confidence intervals. Thus if one conducts enough tests, one will 
inevitably detect cases with minor deviations from normal. Furthermore not every lab 
abnormality carries clinical significance.  
These findings suggest that it is possible to eliminate routine laboratory testing before 
starting the currently recommended HIV PEP regimen in healthy HCP exposed to HIV. 
Although this study was carried out at a single academic institution, we believe that our findings 
are generalizable to other HCP at other institutions. Elimination of routine renal, hematologic 
and hepatic function studies in occupational HIV exposures should be considered as a way to 
improve the timeliness of starting PEP after exposure as well as eliminate the barrier of seeking 
immediate care after exposure beyond obtaining PEP medications.   
Limitations 
  The retrospective nature of the study presented us with two main limitations. One was 
the measurement of adherence to the PEP regimen. While discontinuation of PEP therapy was 
documented in the occupational health record when the source patient testing was negative, there 
was often no explicit mention of adherence to the PEP regimen other than the filling of the 
prescription. However, several recent studies show that the adherence, in the nPEP setting, is 
quite high (Mayer, Mimiaga, Gelman, & Grasso, 2012).  
 Additionally, most of the HCP did not have laboratory studies at 4 weeks, since the PHS 
guidelines now recommend lab draws at baseline and 2 weeks (without explicitly mentioning of 
week 4). It is possible that laboratory values at 4 weeks may have shown some sub-clinical 
abnormalities but at that point the PEP regimen would be discontinued anyway.  
Conclusion 
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 Given our 5-year experience with the current tenofovir-emtricitabine-raltegravir regimen 
and systematic review of safety and efficacy data for this PEP regimen, we are recommending 
that occupational health providers no longer draw routine laboratory studies with the exception 
of baseline and subsequent HIV testing in healthy HCP. Focused laboratory testing may be 
indicated in HCP with underlying diseases (e.g., renal or hepatic dysfunction) 
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Appendix 
Table 1. Study Profiles of Systematic Review 
Study 
Citation 
Design Population Methods Results Quality 
Rating 
(Rockstroh, 
et al., 2013) 
STARTMRK was a 
randomized, 
blinded, double-dummy 
phase III trial of 
raltegravir with 
tenofovir/emtricitabine 
versus efavirenz with 
tenofovir/emtricitabine 
in treatment-naive HIV-
infected adults. 
586 people 
on 6 
continents 
randomized 
1:1 to RAL: 
EFV arms 
281 people 
randomized 
to RAL 
group 
Patient 
diaries and 
pill counts 
for 
adherence.  
 
Investigators 
monitored 
adverse 
events 
Drug-related 
clinical adverse 
events in 146 
raltegravir 
recipients (52.0%) 
 
Abnormal labs in 
56 patients 
(19.9%) who 
received raltegravir 
 
Zero patients 
discontinued due to 
lab abnormalities 
Good 
(Eron, et al., 
2011) (Eron, 
et al., 2011) 
Randomized, controlled, 
double-blind phase 3 
trial.  
Compared RAL daily to 
RAL BID 
775 people 
on 6 
continents 
randomized 
1:1 to RAL 
BID: once-
daily arms 
 
382 
randomized 
to RAL 
group  
Patients 
completed 
diary cards 
for all study 
drugs 
 
Investigators 
monitored 
adverse 
events 
Adverse events 
leading to 
discontinuation 
occurred in 
four (1%)  
 
2.3% had drug-
related lab 
abnormalities.  
 
0 reports of serious 
drug related 
adverse effects, and 
discontinuations 
due to adverse 
effects 
 
Good 
(McAllister, 
et al., 2013) 
Nonrandomized, 
controlled, prospective 
study. Comparing FTC-
TDF with FTC-TDF-
RAL 
86 men 
prescribed 
FTC-TDF-
RAL and 34 
prescribed 
FTC-TDF) at 
2 Australian 
clinics 
Pill counts 
for adherence  
 
Investigators 
monitored 
adverse 
events 
Adherence rate was 
92%. Nine percent 
developed mild 
myalgias, with 4 
developing 
transient grade 4 
elevations in 
creatine kinase, 
which 
spontaneously 
resolved by week 4. 
Fair 
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Table 2. Subject Demographics at Baseline (n=64)  
Variable  
Mean age (years) 35.3 (± 10.3) 
Age range (years) 21- 55] 
- Female 37 (57.9%) 
Exposure route (n) 
- Needlestick 
- Splash 
- Laceration 
- Other  
- Missing 
 
- 38 (61.3%) 
- 14 (22.6%) 
- 17 (11.3%) 
- 3 (4.8%) 
- 2 
Exposure type (n) 
- Clinical 
- Non-clinical a 
- Missing  
 
- 58 (93.5%) 
- 4 (6.5%) 
- 2 
HIV status of source (n) 
- Known b 
- Unknown  
- Missing  
 
- 45 (83.3%) 
- 9 (16.7%) 
- 10 
Chart location (n) 
- Hospital OHS 
- UEOHC 
 
- 53 (82.8%) 
- 11 (17.2%) 
Abbreviations:  HIV = human immunodeficiency virus; OHS = Occupational Health Services;  
UEOHC = University Employee Occupational Health Service 
a Non-clinical exposure type category includes 3 exposures from HIV infected laboratory mice, and 1 
exposure of a detention officer with an unknown source.  
b The ‘Known’ category of HIV status of source includes 3 HIV infected laboratory mice. 
Note: All percentages are calculated excluding the ‘missing’ values of the given characteristic.  
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Table 3: Number of Exposed HCP with Abnormal Lab Values per Time Period 
  Baseline 2weeks 4 weeks 
Hematologic 
dysfunction: 
hemoglobin, ANC (n) 
0 / 60 
 
Subject (53yo male):  
ANC 3.4 x 
1.5x10^9/L 
 
1 / 53 
 
Subject (53yo male): 
ANC 1.4  c x 
1.5x10^9/L 
0 / 18 
 
Subject (53yo male): 
ANC not recorded 
Renal dysfunction: 
GFR (n) 
1 / 61 b 
 
Subject (51yo 
female): GFR 51.8 c 
 mL/min/1.73m2 
 
Subject (23yo 
female): GFR 69.5 
mL/min/1.73m2 
 
Subject (64yo 
female): GFR 73.3 
mL/min/1.73m2 
 
3 / 53 b 
 
Subject (51yo female): 
GFR 52.9 c  
mL/min/1.73m2 
 
Subject (23yo female): 
GFR 58.5 c 
 mL/min/1.73m2 
 
Subject (64yo female): 
GFR 58.5 c 
0 / 17 
 
Subject (51yo female): 
No GFR recorded 
 
 
Subject (23yo female): 
GFR 67.9 
mL/min/1.73m2 
 
Subject (64yo female):  
GFR 68.3 
mL/min/1.73m2 
Hepatic dysfunction: 
AST, ALT, total 
bilirubin (n) 
1 / 62 
 
Subject (39yo male):  
Total bilirubin 2.5 c 
mg/dL  
0 / 51 
 
Subject (39yo male): 
total bilirubin not 
recorded  
 
1 / 18 
 
Subject (39yo male):  
Total bilirubin 1.9 c 
mg/dL 
The denominators represent the number of HCP for which a given lab was drawn. Because the latest PHS 
guidelines recommend drug toxicity monitoring at baseline and 2 weeks (and not explicitly at week 4), 
fewer lab draws were done on week 4. 
a n is the number of HCP who had no missing relevant laboratory data during the specified time frame  
b The same employee appears in multiple time periods, that is, HCP were not removed from the sample if 
they had a hematologic, renal, or hepatic dysfunction.  
c Denotes abnormal lab value, based on the Common Terminology Criteria for Adverse Events 
Where absolute neutrophil count is ANC, and glomerular filtration rate is GFR 
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Data Dictionary 
Variable Description Variable 
Type 
DOB Date of Birth: self-reported date of birth collected from the 
medical record.  
 
Continuous  
DOE Date of exposure: self-reported date of exposure on the 
incident report. 
 
Continuous 
Age_on_Exp Age on exposure: calculated by:  
Date of Exposure, minus the Date of Birth. Divided by 365. 
Rounded to the nearest integer. 
INT((DOE - DOE)/365) 
 
Continuous 
Sex Sex: self-reported sex from the medical record.  
Female = 0, Male = 1. 
 
Dichotomous 
HIV_status_subj HIV status of the subject: derived from the medical record. 
The result of an HIV test of the exposed employee after the 
exposure. 
HIV negative = 0, HIV Positive = 1 
 
Dichotomous 
WBC, HGB, HCT, 
PLATELETS, ANC, 
CREATININE, TBILI, 
AST, ALT, BHCG 
Baseline labs for the WBC, Hgb, Hct, Platelets, ANC, 
Creatinine, Total Bilirubin, AST, ALT, Pregnancy test were 
obtained from EPIC, WebCIS, physical charts, or McLendon 
labs directly. 
To denote baseline, 2 week follow-up, and 4-week follow-
up, each variable ‘_BASE’ , ‘_FU2WEEK’, and 
‘_FU4WEEK’ appended. For instance WBC_BASE, 
WBC_FU2WEEK, and WBC_FU4WEEK represent the 
WBC at baseline, 2 weeks, and 4 weeks respectively. 
 
Continuous 
Regimen Regimen: the HIV PEP regimen was obtained from the 
provider notes in the medical record. Regimen:  
(Tenofovir+emtricitabine+raltegravir )=1,  
(emtricitabine+tenofovir+lopinavir+ritonavir)  = 0 
 
Dichotomous 
EXP_TYPE Exposure type:  was determined by the type of work the 
employee was doing at the time of exposure.  
Research = 0, Clinical = 1. 
 
Dichotomous 
EXP_ROUTE Exposure route:  Determined by 1 of 4 categories in the 
incident report. Categories were splash, needlestick, 
laceration, and ‘other’. ‘other’ included scratch, and cough. 
 
Categorical 
Dept  Department: derived from the incident report. If not 
available in the incident report, they were found in the 
university or hospital employee databases where available.  
Categorical 
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Job_Title Job Title: obtained from the incident report. If not available 
in the incident report, they were found in the university or 
hospital employee databases where available. The categories 
were based on the job titles.  
 
Categorical 
Source_HIV_Status Source HIV Status: obtained from the incident report. If not 
present there, Source HIV Status was located in other 
sections of the medical record (provider’s notes, confidential 
section, etc.) 
 
Dichotomous 
Chart_ Location Chart Location: defines which occupational health clinic the 
exposed employee received follow-up (0=University 
Employee Occupational Health Services; 1= Hospital 
Employee OHS). 
 
Dichotomous 
Hgb2wk-baselineValue Represents the percent change in Hgb from baseline.  
100*(HGB_FU2WEEK - HGB_BASE )/ HGB_BASE 
 
Continuous 
Hgb4wk-baselineValue Represents the percent change in Hgb from baseline.  
100*(HGB_FU4WEEK - HGB_BASE )/ HGB_BASE 
 
Continuous 
ANC2wk-baselineValue Represents the percent change in ANC from baseline.  
100*(ANC_FU2WEEK - ANC_BASE )/ ANC_BASE 
 
Continuous 
ANC4wk-baselineValue Represents the percent change in ANC from baseline.  
100*(ANC_FU4WEEK - ANC_BASE )/ ANC_BASE 
 
Continuous 
GFR-GenderFactor Based on Sex, variable. This is used in calculating the GFR. 
If Sex is Male (Sex=1), then GFR-GenderFactor = 1 
If Sex is Female (Sex=0), then GFR-GenderFactor =  0.742 
Dichotomous 
GFR_Wk4(race=nonblk) Glomeral filtration rate (GFR) was calculated using the 4-
variable Modification of Diet in Renal Disease (MDRD) 
Study equation.  
 
GFR = 175 * Serumcreatinine-1.154 * Age-0.203 * Sex * Race 
Where: Serumcreatinine is the Creatinine at that week;  
Age is the age on exposure;  
Sex is GFR-GenderFactor;  
Race is set to 1. The Race of the subjects could not be 
reliably retrieved with efficiency. As such, every subject was 
assumed to be nonblack. Since people who are nonblack 
have a lower GFR, this lead us to underestimate the GFR in 
black patients. 
(Per the MDRD equation, Black Race = 1.21, and nonblack 
Race = 1) 
 
Continuous 
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Common Terminology Criteria for Adverse Events from the National Cancer Institute 
 
(National Cancer Institute, 2010) 
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